Evidence map›Paper›PMID 36388411›Full record

ArticleNeuro-oncology practice2022

Efficacy and toxicity with radiation field designs and concurrent temozolomide for CNS lymphoma.

Anna M Laucis, Katherine Selwa, Yilun Sun, Michelle M Kim, Kyle C Cuneo, Theodore S Lawrence, Daniel R Wahl, Larry Junck, Yoshie Umemura

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Anna M LaucisDepartment of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0001-9123-5451
Katherine SelwaDepartment of Neurology, University of Michigan Hospital, Ann Arbor, MI, USA.
Yilun SunDepartment of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Michelle M KimDepartment of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Kyle C CuneoDepartment of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Daniel R WahlDepartment of Radiation Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Larry JunckDepartment of Neurology, University of Michigan Hospital, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0002-8203-0400
Yoshie UmemuraDepartment of Neurology, University of Michigan Hospital, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0001-7137-661X
University of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is no consensus on the treatment of central nervous system (CNS) lymphoma refractory to first-line methotrexate-based chemotherapy. Whole brain radiotherapy (WBRT) is sometimes used but may result in unacceptable neurocognitive dysfunction. We examined the efficacy and toxicities of WBRT with or without concurrent temozolomide in CNS lymphoma treatment. Methods: This single-institution IRB-approved retrospective study included adults with CNS lymphoma who received WBRT, either consolidative low-dose WBRT alone or low-dose WBRT with a focal boost to residual disease and were previously treated with high-dose methotrexate. The relationships between the WBRT regimen, concurrent temozolomide, and clinical outcomes and toxicities were assessed using proportional hazards and logistic regression models. Results: A total of 45 patients with a median age of 64 years (range 24-74) treated from 2004 to 2019 were included. In total, 20 patients received concurrent temozolomide. In the WBRT + Boost cohort ( Conclusions: In this study, concurrent temozolomide with radiotherapy in CNS lymphoma was associated with better PFS and was well tolerated. Low-dose WBRT with a boost is a safe and reasonable treatment approach for focal refractory disease. Prospective research that includes rigorous neurocognitive assessments is now warranted.

Indexed as

central nervous systemlymphomatemozolomidewhole brain radiotherapy

Identifiers

PMID36388411
PMCPMC9665068
OpenAlexW4283397516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.